The Effect Of Ranolazine Treatment Administered Before Coronary Artery Bypass Surgery On Perioperative Myocardial Damage In Patients With Stable Angina Pectoris
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective:Ranolazineisapiperazinederivativethathasbeenapprovedasanantianginal agent.Itisprimarilyusedasasecondlineantianginalagentinstablecoronaryarterydisease.Thestudywasdesignedconsideringthattheactiveingredientranalozine,\rwhich has antiischemic effectsthrough ischemic sodiumchannels, can reduce ischemia in the perioperative period and reduce\rthe frequency of perioperative myocardialinfarction.\rMethods: The study included patients with stable angina pectoris who underwent coronary angiography between January\r1, 2015 and June 30, 2016 at Koşuyolu Training and Research Hospital and who were diagnosed with multi-vessel disease\ror LMCA disease, and then for whom the joint council of Cardiology-Cardiovascular Surgery made a decision in favor of\rcoronary artery bypass grafting.\rResults: The mean age was 61.2 ± 8.6 years in the ranolazine group, while the mean age of the patients receiving standard\rtherapy was 57.9 ± 8.8 years (p = 0.073).The EuroSCOREs of the patients before the operation which were used to predict\rintraoperative mortality were similar. Mean troponin value of Group 1 patients at 0 hour was 1.70 (1.13-2.77), while mean\rtroponin value of the patients in Group 2 at 0 hour was 2.76(1.69-6.20)(p=0,01).\rConclusion:In the presentstudy,the immediate postoperative troponin 0 valuewasfound to be lowerin the ranolazine group.\rThere was no statistical difference in terms of troponin valuesmeasured at 12 and 24 hours.In thisstudy,we showed that early\rmyocardial damage was significantly reduced with ranolazine treatment.
Açıklama
Anahtar Kelimeler
Kaynak
Kocaeli Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
11
Sayı
1
